Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Patrizi A., rizzoli L., Vespignani M. F., Fanti P. A.
Università degli Studi - Bologna, Dipartimento di Medicina Clinica, Specialistica e Sperimentale, Sezione di Clinica Dermatologica
Background. Topical treatment of verrucae with salicylic acid therapy has been well known for many years. Recently, a new transdermal drug delivery system has been proposed for treatment of verrucae.
Methods. From January 1997 to March 1998, 30 children affected by viral warts, 21 males and 9 females ranging in age from 4 to 14 years, were enrolled in this study. The sites involved were the feet in 16 cases (13 cases the sole and 3 cases the toes) and the hands in 16 cases (7 cases the palms, 9 cases the dorsal surface of hands or fingers). In 3 patients verrucae were present at the same time on feet and hands. Patches were used consisting of a keraya gum glycol matrix containing salicylic acid USP, 15%. The product applications were preceded by moisturizing the skin surface with water using a cotton tipped applicator. Treatment applications were held in place with bandaging material and then removed after 12 hours. On sole verrucae two applications per day were made, while on the other sites one application per day. This wart therapy was continued for 4-10 weeks. Patients were controlle every 2 weeks.
Results. At the end of the treatment 19 patients (63.3%) obtained a complete recovery, 4 patients (13.3%) a remission >60%, 4 patients (13.3%) a regression <60% and in 3 patients (10%) no results were obtained.
Conclusions. The results suggest that the transdermal delivery system of salicylic acid utilized in this study offers several advantages; in fact, a good response was observed in about 70% of the patients and this treatment did not present local adverse reaction in almost any of the studied children.